We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-2.52%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$196M
AUM Growth
-$77.5M
(-28%)
Cap. Flow
-$87.5M
Cap. Flow
% of AUM
-44.72%
Top 10 Holdings %
Top 10 Hldgs %
56.4%
Holding
63
New
21
Increased
5
Reduced
15
Closed
19
Avg Time Held Equity + Options
0.4
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$16.1M |
| 2 |
Medtronic
MDT
|
+$6.07M |
| 3 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$4.21M |
| 4 |
Abbott
ABT
|
+$4.16M |
| 5 |
Cardinal Health
CAH
|
+$2.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$12.9M |
| 2 |
SHPG
Shire pic
SHPG
|
+$10.9M |
| 3 |
Eli Lilly
LLY
|
+$10.1M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$9.65M |
| 5 |
AGN
Allergan plc
AGN
|
+$9.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.65% |
| 2 | Miscellaneous | 32.43% |
| 3 | Industrials | 1.3% |
| 4 | Consumer Discretionary | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Ascendis Pharma A/S
ASND
$14.8B
| $2.69M | 1.37% |
202,520
+15,300
| +8% | +$236K |
2015 Q2
4 quarters
|
|
|
FOMX
27
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.57M | 1.31% |
405,374
-167,254
| -29% | -$1.11M |
2015 Q2
4 quarters
|
|
28
TriNet
TNET
$3.25B
| $2.55M | 1.3% |
122,563
-191,112
| -61% | -$3.5M |
2016 Q1
1 quarter
|
|
|
FWP
29
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $2.26M | 1.16% |
17,782
-13,133
| -42% | -$1.77M |
2015 Q4
2 quarters
|
|
|
DMK
30
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
| $1.92M | 0.98% |
9,778
-8,255
| -46% | -$3.81M |
2014 Q4
6 quarters
|
|
|
31
McKesson
MCK
$117B
| $1.87M | 0.95% |
10,000
-73,600
| -88% | -$12.9M |
2015 Q4
2 quarters
|
|
32
IQVIA
IQV
$43.9B
| $1.86M | 0.95% |
+28,541
| New | +$1.91M |
2016 Q2
0 quarters
|
|
33
PUT
DELISTED
Sage Therapeutics
SAGE
| $1.71M | 0.87% |
+56,800
| New | +$1.89M |
2016 Q2
0 quarters
|
|
|
AFAM
34
DELISTED
Almost Family Inc
AFAM
| $1.21M | 0.62% |
+28,452
| New | +$1.17M |
2016 Q2
0 quarters
|
|
|
ADMS
35
DELISTED
Adamas Pharmaceuticals
ADMS
| $855K | 0.44% |
56,500
+36,500
| +183% | +$602K |
2015 Q3
3 quarters
|
|
36
DELISTED
Molecular Templates, Inc.
MTEM
| $847K | 0.43% |
8,082
-15,871
| -66% | -$1.14M |
2015 Q4
2 quarters
|
|
37
Viking Therapeutics
VKTX
$3.2B
| $699K | 0.36% |
+554,382
| New | +$731K |
2016 Q2
0 quarters
|
|
38
Spyre Therapeutics
SYRE
$7.47B
| $690K | 0.35% |
+5,675
| New | +$1.09M |
2016 Q2
0 quarters
|
|
|
OASM
39
DELISTED
Oasmia Pharmaceutical AB
OASM
| $424K | 0.22% |
123,000
| – | – |
2015 Q4
2 quarters
|
|
|
PFNX
40
DELISTED
Pfenex Inc.
PFNX
| $411K | 0.21% |
49,092
-614,084
| -93% | -$4.96M |
2014 Q4
6 quarters
|
|
|
TEAR
41
DELISTED
TearLab Corporation
TEAR
| $407K | 0.21% |
+63,544
| New | +$465K |
2016 Q2
0 quarters
|
|
|
PETX
42
DELISTED
Aratana Therapeutics, Inc.
PETX
| $378K | 0.19% |
+59,869
| New | +$385K |
2016 Q2
0 quarters
|
|
|
IMNP
43
DELISTED
Immune Pharmaceuticals Inc.
IMNP
| $79K | 0.04% |
9,883
| – | – |
2015 Q3
3 quarters
|
|
|
44
Alnylam Pharmaceuticals
ALNY
$31B
| – | – |
-153,778
| Closed | -$9.65M | – |
|
45
Editas Medicine
EDIT
$361M
| – | – |
-7,714
| Closed | -$266K | – |
|
46
PUT
Jazz Pharmaceuticals
JAZZ
$13.6B
| – | – |
-247,400
| Closed | -$32.3M | – |
|
|
47
Eli Lilly
LLY
$1.12T
| – | – |
-140,392
| Closed | -$10.1M | – |
|
48
Lantheus
LNTH
$6.51B
| – | – |
-446,098
| Closed | -$843K | – |
|
49
InspireMD
NSPR
$21.3M
| – | – |
0
| – | -$4K |
2015 Q1
5 quarters
|
|
50
Novartis
NVS
$286B
| – | – |
-106,007
| Closed | -$6.88M | – |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Sio Capital Management held 63 positions worth $196M, down 28% from $273M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Sio Capital Management withdrew a net $87.5M in Q2 2016, closing 19 positions and reducing 15 holdings. Its most notable exit was Shire pic, an estimated $10.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 77% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, Sio Capital Management opened a new position in Biogen worth $14.8M.
- Sio Capital Management's largest Q2 2016 buy was Biogen: 61,000 shares worth $14.8M.
- Sio Capital Management added most to Cardinal Health in Q2 2016, an estimated $2.85M increase.
- Sio Capital Management's biggest Q2 2016 reduction was McKesson, cutting an estimated $12.9M.
- Sio Capital Management fully exited Shire pic in Q2 2016, selling an estimated $10.9M.
- Sio Capital Management's ten largest holdings make up 56% of its $196M portfolio in Q2 2016.
- Sio Capital Management opened 21 new positions and closed 19 in Q2 2016.
- Sio Capital Management's portfolio value fell 28% quarter-over-quarter to $196M.
Based on Sio Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.